Eva Essig
Profile
Eva Essig worked as a Vice President at Northfield Laboratories, Inc.
Former positions of Eva Essig
| Companies | Position | End |
|---|---|---|
Northfield Laboratories, Inc.
 Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Corporate Officer/Principal | 2009-11-09 |
Experiences
Positions held
Linked companies
| Private companies | 1 |
|---|---|
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Health Technology |
- Stock Market
- Insiders
- Eva Essig
